TY - JOUR
T1 - A new score based on biomarker values to predict the prognosis of locally advanced cervical cancer
AU - Maulard, Amandine
AU - Chargari, Cyrus
AU - Faron, Matthieu
AU - Alwohaibi, Asim
AU - Leary, Alexandra
AU - Pautier, Patricia
AU - Genestie, Catherine
AU - Morice, Philippe
AU - Gouy, Sebastien
N1 - Publisher Copyright:
© 2020
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Objective: To define a prognostic score based on pretreatment values of leucocyte, platelet and hemoglobin in locally advanced cervical cancer (LACC). Material and methods: We conducted a prospective study of 238 patients for LACC with negative PET imaging in the para-aortic (PA) area and who were undergoing laparoscopic PA lymphadenectomies. All patients were treated with chemo-radiation and brachytherapy. Results: Patients had clinical International Federation of Gynecology and Obstetrics stages IB2 (n = 76), IIA (n = 13), IIB (n = 122), III (n = 18) or IVA (n = 9). We identified three biological parameters (at the time of diagnosis) with three cut-offs which impacted disease free survival (DFS) and overall survival (OS): <12 g/dL for hemoglobin, >10,000/μL for leucocyte and >300 × 109/L for platelet. A score is calculated, as shown in the table below, by adding the scores of all three biological parameters together (with a maximum score of three). [Table presented] DFS at 36 months was 87.3% [78.3–97.4], 58% [45–74.6], 79.1% [71.1–88], 58% [45–74.6] and 56.8% [37.8–85.4] for scores of 0, 1, 2 and 3 respectively. OS at 36 months was 92.6% [84.9–100], 84% [76.6–92.1], 62.5% [48.9–79.9] and 67% [46.8–96] for scores of 0, 1, 2 and 3 respectively. Conclusion: This score includes three biomarkers with easily remembered cut-offs that allow us to identify, at the time of diagnosis, those patients with a high risk of relapse (scores of two or three) and those requiring dose escalation.
AB - Objective: To define a prognostic score based on pretreatment values of leucocyte, platelet and hemoglobin in locally advanced cervical cancer (LACC). Material and methods: We conducted a prospective study of 238 patients for LACC with negative PET imaging in the para-aortic (PA) area and who were undergoing laparoscopic PA lymphadenectomies. All patients were treated with chemo-radiation and brachytherapy. Results: Patients had clinical International Federation of Gynecology and Obstetrics stages IB2 (n = 76), IIA (n = 13), IIB (n = 122), III (n = 18) or IVA (n = 9). We identified three biological parameters (at the time of diagnosis) with three cut-offs which impacted disease free survival (DFS) and overall survival (OS): <12 g/dL for hemoglobin, >10,000/μL for leucocyte and >300 × 109/L for platelet. A score is calculated, as shown in the table below, by adding the scores of all three biological parameters together (with a maximum score of three). [Table presented] DFS at 36 months was 87.3% [78.3–97.4], 58% [45–74.6], 79.1% [71.1–88], 58% [45–74.6] and 56.8% [37.8–85.4] for scores of 0, 1, 2 and 3 respectively. OS at 36 months was 92.6% [84.9–100], 84% [76.6–92.1], 62.5% [48.9–79.9] and 67% [46.8–96] for scores of 0, 1, 2 and 3 respectively. Conclusion: This score includes three biomarkers with easily remembered cut-offs that allow us to identify, at the time of diagnosis, those patients with a high risk of relapse (scores of two or three) and those requiring dose escalation.
KW - Biomarkers
KW - Locally advanced cervical cancer
KW - Prognostic score
UR - http://www.scopus.com/inward/record.url?scp=85089599618&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2020.08.002
DO - 10.1016/j.ygyno.2020.08.002
M3 - Article
C2 - 32828580
AN - SCOPUS:85089599618
SN - 0090-8258
VL - 159
SP - 534
EP - 538
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -